Jun Yao on Muck Rack

Jun Yao

  • Contributor, Pubs.rsc.org
As seen in: AIChE Journal, Nature, Wiley Online Library, PLOS, PLOS Biology, PLOS ONE, BMJ Open, Elsevier, Frontiers, Frontiers in Public Health and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jun

Contact Jun, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Atomically precise Au 8 Pd 1 (DPPF) 4 2+ catalyst orchestrates the synthesis and utilization of hydrogen peroxide

|
By Xiao Cai, Jun Yao, Shuangshuang Huang, Yan Zhu
| Nature Verified
Abstract Atomically precise metal clusters that merge structural clarity, functional modularity, and tunable spatial programmability have gained momentum over the past decade. Here, we report the catalysis of an atomically precise Au8Pd1(DPPF)42+ (DPPF = 1,1’-bis(diphenylphosphino)ferrocene) cluster in the synthesis and utilization of hydrogen peroxide.
Open in Who Shared Issue with article?

Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial

|
By Yi Pan, Xuening Yang, Qing Zhou, Yanqiu Zhao, Guang Han, Qingsong Pang, Zhenfa Zhang, Qifeng Wang, Jun Yao, Hui Wang, Weihua Yang, Baogang Liu, Qixun Chen, Xianghui Du, Kaican Cai, Baosheng Li, Yunchao Huang, Xiao Li, Yijun Jia, Wei Shi, Yi-Long Wu
| Nature Verified
Abstract TRAILBLAZER is a proof-of-concept phase 2 study (ClinicalTrials.gov, NCT04580498) of neoadjuvant retlirafusp alfa (an anti-PD-L1/TGF-β bifunctional agent) in unresectable stage III non-small cell lung cancer (NSCLC) not harboring EGFR or ALK alterations. During induction, retlirafusp alfa was administered either with chemotherapy or as monotherapy, followed by surgery or radiotherapy as assessed by a local multidisciplinary team and consolidation retlirafusp alfa.
Open in Who Shared Issue with article?

Controllable Construction of Microhelical Flows for Precise Regulation of Structural Characteristics of Microhelices Click to copy article link Article link copied!

|
By You-Qiang Xia, Jun Yao, Tao-Xian Zhang
| dx.doi.org
Open in Who Shared Issue with article?
See all 145 licensed articles (162 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified